Global Deferasirox Tablet Market Research Report 2024
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Deferasirox Tablet Market Research Report 2024
Deferasirox is an oral iron chelator. Its main use is to reduce chronic iron overload in patients who are receiving long-term blood transfusions for conditions such as beta-thalassemia and other chronic anemias.
According to Mr Accuracy reports new survey, global Deferasirox Tablet market is projected to reach US$ 113.8 million in 2029, increasing from US$ 323 million in 2022, with the CAGR of -5.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Deferasirox Tablet market research.
The Exjade market is driven by the increasing prevalence of iron overload conditions, such as transfusional hemosiderosis in patients receiving regular blood transfusions. Exjade, a medication containing deferasirox, is used to manage iron overload by chelating excess iron and promoting its elimination from the body. The drug's efficacy in preventing iron-related complications has contributed to its growing adoption in the treatment of thalassemia and other transfusion-dependent disorders. Moreover, advancements in medical research and improved patient access have further propelled market growth. However, challenges include the high cost of the medication, potential side effects, and the need for continued research to optimize dosing and monitoring strategies. Overcoming these challenges and expanding access to affordable and safe treatments will be crucial for the sustained growth of the Exjade market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Deferasirox Tablet market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Novartis
Segment by Type
125mg
250mg
500mg
Hospital
Pharmacy
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Deferasirox Tablet report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
According to Mr Accuracy reports new survey, global Deferasirox Tablet market is projected to reach US$ 113.8 million in 2029, increasing from US$ 323 million in 2022, with the CAGR of -5.7% during the period of 2024 to 2029. Influencing issues, such as economy environments, COVID-19 and Russia-Ukraine War, have led to great market fluctuations in the past few years and are considered comprehensively in the whole Deferasirox Tablet market research.
The Exjade market is driven by the increasing prevalence of iron overload conditions, such as transfusional hemosiderosis in patients receiving regular blood transfusions. Exjade, a medication containing deferasirox, is used to manage iron overload by chelating excess iron and promoting its elimination from the body. The drug's efficacy in preventing iron-related complications has contributed to its growing adoption in the treatment of thalassemia and other transfusion-dependent disorders. Moreover, advancements in medical research and improved patient access have further propelled market growth. However, challenges include the high cost of the medication, potential side effects, and the need for continued research to optimize dosing and monitoring strategies. Overcoming these challenges and expanding access to affordable and safe treatments will be crucial for the sustained growth of the Exjade market.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Deferasirox Tablet market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
By Company
Novartis
Segment by Type
125mg
250mg
500mg
Segment by Application
Hospital
Pharmacy
Consumption by Region
North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Indonesia
Thailand
Malaysia
Philippines
Vietnam
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
U.A.E
The Deferasirox Tablet report covers below items
Chapter 1Product Basic Information (Definition, Type and Application)
Chapter 2Manufacturers’ Competition Patterns
Chapter 3Country Level Sales Analysis
Chapter 4Product Type Analysis
Chapter 5Product Application Analysis
Chapter 6Manufacturers’ Outline
Chapter 7Industry Chain, Market Channel and Customer Analysis
Chapter 8Market Opportunities and Challenges
Chapter 9Market Conclusions
Chapter 10Research Methodology and Data Source
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices